Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label 2-Year Extension of a Phase 3 Trial

Autor: Brunner HI, Ruperto N, Zuber Z, Cuttica R, Keltsev V, Xavier RM, Burgos-Vargas R, Calvo Penades I, Silverman ED, Espada G, Ferrandiz Zavaler M, Kimura Y, Duarte C, Job-Deslandre C, Joos R, Douglass W, Wimalasundera S, Bharucha KN, Wells C, Lovell DJ, Martini A, De Benedetti F, Paediatric Rheumatology International Trials Organisation (PRINTO), the Pediatri

Publikováno v: ARTHRITIS & RHEUMATOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname

Report the 2-year efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis (pcJIA).

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::09d1987516c5355c41091a12e6ee26a6
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=13296